Autologous Cell-derived Tissue Engineered Cartilage for Repairing Articular Cartilage Lesions
Launched by CHINESE PLA GENERAL HOSPITAL · May 11, 2016
Trial Information
Current as of April 29, 2025
Unknown status
Keywords
ClinConnect Summary
Injured articular cartilage has limited capacity for self repair. Without timely, early and effective treatment, damage to the articular cartilage progressively worsens, resulting in joint swelling, pain and dysfunction. The patient ultimately develops osteoarthritis and will be required to undergo artificial joint replacement. Clinical therapy for cartilage damage includes microfracture surgery and autologous osteochondral transplantation. However, the microfracture technique is limited to small-scale damage, and autologous osteochondral transplantation is hindered by limited supply. With ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with full-thickness cartilage injury in knee and ankle joints
- • Patients with normal joint movement and stable joint (without injury or less than 1/3 excision of the meniscus; normal cruciate ligament, lateral and medial collateral accessory ligament, or normal Q angle and patellofemoral joint trajectory after transplantation, or corrected to normal by surgery), without valgus or varus deformity
- • Patients 14-50 years of age.
- • Patients with focal cartilage defects diagnosed by arthroscopy, Outerbridge III/IV grade, cartilage defect size 2.5-10 cm2, intact articular surface (lower than grade II injury according to Outerbridge classification), one or two lesions in the same joint.
- • Patients and their families are informed of the treatment and provide signed informed consent.
- Exclusion Criteria:
- • Poor health
- • Blood diseases
- • Topical steroid therapy within three months
- • Bleeding tendency
- • Drug addiction (including narcotic, anesthetic or alcohol addiction)
- • Inflammatory joint disease (specific or non-specific arthritis)
- • Contagious viral infection
- • Metabolic diseases (gout or rheumatism)
- • Body mass index \> 30 kg/m2
- • Pregnant or lactating women, or planning to become pregnant within 1 year after initial registration
- • Psychological mental illness, cannot cope with rehabilitation
About Chinese Pla General Hospital
The Chinese PLA General Hospital, a prominent military medical institution in Beijing, serves as a leading sponsor for clinical trials, focusing on advancing healthcare through innovative research and development. Renowned for its comprehensive medical services and cutting-edge research capabilities, the hospital is committed to improving patient outcomes through rigorous scientific investigation and collaboration with various stakeholders in the healthcare sector. With a multidisciplinary approach and a strong emphasis on evidence-based practices, the Chinese PLA General Hospital aims to contribute significantly to the global medical community by facilitating the development of safe and effective therapeutic interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Quanyi Guo, Ph.D
Principal Investigator
Institute of Orthopedics, Chinese PLA Hospital, Beijing, China
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials